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Abstract
Brain morphology significantly differs between the sexes. It has been shown before that some of these differences
are attributable to the sex-specific hormonal milieu. Brain-derived neurotrophic factor (BDNF) is involved in myriads
of neuroplastic processes and shows a sexual dimorphism. Transsexual persons may serve as a model to study sex
steroid-mediated effects on brain plasticity. We have recently demonstrated that serum levels of BDNF are reduced
in transwomen following 12 months of cross-sex hormone treatment. We now wanted to look at the effects of
testosterone treatment on BDNF in transmen. In contrast to our initial hypothesis, BDNF levels did not significantly
change, despite dramatic changes in the sex-hormonal milieu. Our data indicate that testosterone does not seem
to play a major role in the regulation of BDNF in females.
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Findings
Introduction
Men and women show distinct differences with regard
to their macroscopic brain architecture though the
relevance of these findings on a functional level is far
from being elucidated. Progress in magnetic resonance
imaging techniques has led to a growing number of
studies investigating gender-specific features in brain
morphology. Among others, this includes disparities in
total volume and white-to-gray-matter ratios as well as
regional variances in distinct areas of the brain [1, 2].
While some of these differences seem to have their origin
in the prenatal period of development, others first emerge
with the onset of puberty [3]. However, sex-specific plasti-
city of the brain is not restricted to younger individuals.
Also in adulthood, drastic changes in the sex-hormonal
milieu as seen in androgen deprivation therapy in men
with prostate cancer [4] or in endocrine treatment of gen-
der dysphoric individuals are still capable of influencing
brain morphology [5]. It is therefore obvious that the
shaping of the human brain in a sex-dependent manner
is influenced by sex steroids. It has been demonstrated
before that sex steroids are directly influencing the
neuroplastic potential of the brain such as modulating
neurogenesis or neurite outgrowth [6, 7]. In particular,
gender dysphoric individuals may serve as a model to
study the effects of sex steroids on brain plasticity.
Gender dysphoria (GD) is a condition characterized by
a strong gender identification that is opposite to the
gender an individual was initially assigned to at birth [8].
An etiological reason for GD has not been identified yet,
but biological factors have been discussed that might
influence gender identity [9–11], as many patients report
on GD from the beginning of earliest childhood on [12].
Medical options to overcome the feeling of distress,
commonly emerging from the experienced incongruence
between physical appearance and gender identification,
consist in the initiation of a so-called cross-sex hormone
(CSH) treatment and/or gender reassignment surgery. It
has been shown before that brain-derived neurotrophic
factor (BDNF) levels are reduced in hormonally treated
transwomen (male-to-female individuals) in comparison
to men from the general population and this has also
been suggested to represent an etiological contributor
* Correspondence: mauer@psych.mpg.de
1Endocrinology, Diabetology and Internal Medicine, Max Planck Institute of
Psychiatry, Kraepelinstr. 2-10, 80804 Munich, Germany
Full list of author information is available at the end of the article
© 2016 Auer et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Auer et al. Biology of Sex Differences  (2016) 7:1 
DOI 10.1186/s13293-015-0055-5
or marker for GD [13]. We could recently demonstrate
that 1 year of CSH in transwomen results in a significant
drop in peripheral BDNF levels which makes an explan-
ation focusing on the etiology for GD less convincing [14].
This is of certain importance as it has been shown before
that BDNF levels are lower in women than in men [15].
As BDNF is involved in a variety of neuroplastic processes
such as synaptogenesis, neurogenesis, or myelination [16]
and has also been reported to have an impact on macro-
scopic brain architecture [17, 18], it may therefore play a
role in gender-specific and sex steroid-driven differences
in brain architecture [19]. BDNF is expressed in a variety
of tissues, and BDNF levels in serum are regarded to be
closely related to BDNF concentrations in the brain [20]
and may provide information on BDNF release and uptake
by the central nervous system [21].
Studies investigating the effects of testosterone on
BDNF in humans in general, as well as in the setting of
CSH in transmen are missing so far. We hypothesized
that BDNF levels in transmen would decrease after 1 year
of CSH in a well-characterized cohort being part of the
European Network for the Investigation of Gender In-
congruence (ENIGI), vice versa to the observation made
in transwomen. As platelets are the major peripheral
source of BDNF and a significant correlation of BDNF
with platelet count has been reported [22], but was not
assessed in ENIGI, we also investigated in a retrospective
analysis within another cohort, if CSH has an effect on
platelet characteristics in transmen.
Material and methods
Participants were part of the ENIGI, a collaboration of
four European gender identity clinics (Amsterdam, Ghent,
Hamburg, and Oslo) to study the diagnostics and treatment
of GD [23]. Subjects included had been exclusively treated
at the Department of Endocrinology at the Ghent Univer-
sity Hospital between February 2010 and August 2012. All
transmen that participated (N = 29) were of Caucasian ori-
gin and hormone-naïve at first visit including no use of any
hormonal contraceptives at baseline. CSH was initiated
with 1000-mg testosterone undecanoate (Nebido®, Bayer)
every 12 weeks. All participants gave written informed con-
sent. In addition, we retrospectively evaluated data that
were available from the chart files of transmen (N = 38) that
had been treated at the endocrine outpatient unit of the
Max Planck Institute of Psychiatry in Munich (MPIP),
Germany, between 2006 and 2014 and of whom data on
platelets were available from at least two time-points within
an 18-month observation period. Here, all patients had
been treatment-naïve at baseline and were subsequently
treated with either testosterone enanthate 250 mg every
2–3 weeks or testosterone gel 50 mg per day. The study
was approved by the ethical review board of the Ghent
University Hospital and the Ludwig Maximilian University
in Munich and conducted in accordance with the Declar-
ation of Helsinki.
Medical history and examination
Assessment of data on medical history, including comor-
bidities, mood, and lifestyle parameters such as medication
intake, smoking history, and physical exercise as well as a
detailed description of the assessments of anthropometry
and laboratory measures has been reported before for the
ENIGI cohort [24]. Briefly, body weight was measured in
light indoor clothing without shoes to the nearest 0.5 kg.
Blood drawings took place in the morning between 8:00
and 9:00 a.m. following an overnight fast. After a clotting
period of 30–60 min, serum was centrifuged and stored
at −80 °C until analysis. 17-β-Estradiol (E2) and testos-
terone were determined using liquid chromatography
tandem mass spectrometry (AB Sciex 5500 triplequadru-
pole mass spectrometer; AB Sciex, Toronto, Canada) in
the ENIGI cohort and by an electrochemiluminescence
immunoassay in an automated analyzer (Elecsys 2010;
Roche Diagnostics, Mannheim, Germany) in the MPIP
cohort. For information on the methods of the determin-
ation of follicle-stimulating hormone (FSH), luteinizing hor-
mone (LH), and sex hormone-binding globulin (SHBG)
and interassay coefficients of variance (CV), please see [24].
Endogenous levels of BDNF were measured as described
previously [22, 25]. Platelets were analyzed by means of
low-frequency detection with sheath flow technology using
an automated hematologic analyzers (XE 2100®, Sysmex,
Kobe, Japan).
Within the ENIGI study group, seven subjects were
taking selective serotonin reuptake inhibitors (SSRIs) at
baseline due to a positive history of major depression
and one was taking haloperidol due to schizophrenia.
No subject had started any new psychopharmacological
therapy or had been hospitalized for psychiatric reasons,
while two patients stopped their medication during
follow-up. In the MPI cohort at baseline, two patients
were taking SSRIs and one patient a tricyclic antidepres-
sant due to major depression and two subjects took
atypical antipsychotics, one due to schizoaffective dis-
order and another due to bipolar disorder. Of these, one
patient terminated intake of SSRIs during the observa-
tion period. Patients with a recent history of psychiatric
comorbidity and current psychiatric medication intake
were excluded in a subanalysis.
Statistical analysis
Statistical analysis was carried out using PASW 18.0
(SPSS Inc., Chicago, IL). Data are reported as means
(±S.E.M.). For longitudinal comparison, a repeated measure
analysis of variance (ANOVA) was used for metric variables
and the Wilcoxon signed-rank test or McNemar’s test for
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ordinal, respectively, dichotomous variables. Significance
was evaluated at a probability of 5 % or less.
Results
As expected, several months of CSH in transmen of the
ENIGI as well as of the MPIP sample resulted in a signifi-
cant change in the sex-hormonal milieu in a cross-sex way
(Table 1). However, in contrast to our initial hypothesis,
we did not observe any statistically significant effect of the
treatment on BDNF levels (p = 0.795) (Table 1). This did
also not change if excluding those subjects who were
taking any psychiatric medication at baseline (data not
shown). There was no significant effect of CSH on
platelet count (p = 0.952) or volume (p = 0.663) in the
Munich cohort. The transmen from Ghent and the cohort
from Munich did not significantly differ at baseline with
regard to BMI (24.2 kg/m2 ± 1.0 vs. 23.6 kg/m2 ± 0.8, p =
0.435), age (29.1 years ± 1.1 vs. 27.2 years ± 1.1; p = 0.069)
and did not include significantly more or less active
smokers (24.1 vs. 15.8 %, p = 0.075).
Discussion
In the present study, we demonstrate that 12 months of
cross-sex hormone treatment do not significantly affect
serum BDNF levels in transmen. This was against our
initial hypothesis as we had expected that BDNF levels
would rise vice versa to the decrease in transwomen we
and others had observed before [13, 14].
Men in general seem to have higher peripheral levels
of BDNF than women, and it has been suggested that
the differences in platelet content/uptake of BDNF be-
tween men and women may explain this observation,
though differences in BMI are also a potential con-
founder in this regard [15].
That sex steroids do play a role in peripheral BDNF
regulation in natal females is supported by the fact that
women with amenorrhea as well as postmenopausal
women have decreased BDNF levels and hormone re-
placement therapy results in restoration up to levels seen
in fertile women [26]. Cubeddu and colleagues reported
that BDNF is increased in the second half of the menstrual
cycle [27]. With regard to sex steroids, the second—luteal
phase—of the menstrual cycle is primarily characterized
by the presence of progesterone [28] but also by an in-
crease in androgen secretion in comparison to the follicu-
lar phase including a significant peak at midcycle [29].
That progesterone is a potential confounder is supported
by the fact that progesterone is at least capable of increas-
ing central BDNF release, potentially thereby mediating
some of its suggested neuroprotective effects [30]. Proges-
terone levels were not available from the ENIGI study, and
though levels of LH, FSH, and estradiol allow a rough
estimate of the cycle phase, we cannot rule out that
differences in cycle phase between the subjects at base-
line have influenced the results of our study.
Our findings speak against a role of peripheral BDNF
for the observed increase in brain volume in transmen
following CSH [31, 32]. Only few studies have investi-
gated the direct effects of testosterone on BDNF levels,
and there is in particular a paucity of studies that have
been performed in human subjects. Rodent studies indi-
cate that testosterone withdrawal in males subsequent to
gonadectomy decreases BDNF within the hippocampus
[33] as well as in certain motoneurons [34]. One study
did report on increased BDNF levels in women suffering
from polycystic ovary syndrome (PCOS), which is char-
acterized among others by the presence of hyperandro-
genemia [35]. However, in this study, this finding was
attributed to an increase of BDNF release from the
ovaries as BDNF was also significantly elevated in the
follicular fluid of these women.
The fact that CSH in transmen results in a decrease in
BDNF levels, while BDNF remains unaffected by testoster-
one treatment in transwomen, could suggest that other
mechanisms interfere with peripheral BDNF release that
might mask the effects of testosterone on BDNF in trans-
men. Though platelets were not measured in ENIGI, we
did not observe any alterations in platelet count or volume
in transmen in a comparable patient and treatment
setting, making an interfering effect of this potential
confounder unlikely. As this does not exclude the pos-
sibility that the reported decrease in BDNF in trans-
women was mediated by a decrease in platelet counts
in these patients, we also took a look on transwomen
that had been treated at the MPIP with regard to
platelet characteristic (Additional file 1: Table S1).
Interestingly, while platelet counts were not affected by
CSH in transmen, we observed a small, albeit significant
increase in platelet counts in transwomen. This indicates
that estradiol affects thrombocyte formation or release
and is therefore in line with the fact that platelet counts
are higher in women compared to men [36].
It speaks however against a direct effect of total plate-
let counts on the earlier observed reduction in BDNF
levels in transwomen. Increased platelet counts should
otherwise have resulted in an increase and not a de-
crease of serum BDNF [10]. Yet, CSH may alter BDNF
levels by directly affecting the BDNF release from plate-
lets. To our knowledge, there is no study available that
has investigated the direct effects of sex steroids on
BDNF release in vitro. However, testosterone has shown
to induce platelet activation [37], and this in turn has
been associated with BDNF release [38].
Although it is suggested that platelets are the major
peripheral source of BDNF, we can however not exclude
that counteracting effects with regard to peripheral
BDNF release are present in transmen involving ovarian
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Table 1 BDNF, general characteristics, thrombocyte measures
Baseline After 12 months
Mean S.E.M. Mean S.E.M. p
ENIGI transmen
General characteristics
Age (years) 29.1 1.8
BMI (kg/m2) 24.2 1.0 25.2 0.9 0.016
Weight (kg) 66.5 3.1 69.8 3.0 0.007
Waist (cm) 77.4 2.6 79.8 2.5 n.s.
Laboratory measures
BDNF (pg/ml) 5635.1 291.0 5573.4 302.2 n.s.
FSH (U/L) 6.2 1.5 4.5 2.1 n.s.
LH (U/L) 8.3 1.6 10.4 4.8 n.s.
Estradiol (pg/mL) 116.5 14.5 51.6 8.7 0.002
Testosterone total (ng/dL) 42.1 8.4 653.3 44.2 <0.001
Testosterone free (nmol/L) 0.4 0.1 13.6 1.2 <0.001
SHBG (nmol/L) 78.0 8.9 36.2 2.7 <0.001
Lifestyle
Sports index 2.9 0.9 2.8 0.9 n.s.
Work index 2.8 0.9 3.0 0.9 n.s.
Freetime index 2.8 0.9 3.0 0.9 n.s.
N % N %
Current smoking 7 24.1 3 10.2 n.s.
Baseline 3–7 months 8–18 months
Mean S.E.M. Mean S.E.M. Mean S.E.M.
MPIP transmen
General characteristics
Age (years) 27.2 0.6
BMI (kg/m2) 23.6 0.8 24.8 0.8 24.9 0.8 <0.001
Laboratory measures
FSH (U/L) 6.3 0.6 5.8 0.9 12.8 5.3 n.s.
LH (U/L) 12.2 2.2 5.9 1.5 9.8 3.3 0.01
Estradiol (pg/mL) 113.2 17.5 129.3 42.8 66.0 11.2 0.022
Testosterone total (nmol/L) 3.0 0.8 24.3 12.8 2.5 3.2 <0.001
Lifestyle
Current smoking N % N % N %
Yes 6 15.8 5 13.2 4 10.5 n.s
No 32 84.2 28 73.7 28 73.7 n.s.
Not documented 5 13.2 6 15.8 n.s
Thrombocyte measures Mean S.E.M. Mean S.E.M. Mean S.E.M.
Thrombocyte count (10^9/l) 270.3 11.4 270.1 11.5 277.6 26.3 n.s.
Mean thrombocyte volume (fl) 10.3 0.2 10.4 0. 2 10.4 0.2 n.s.
ENIGI European Network for the Investigation of Gender Incongruence, BDNF brain-derived neurotrophic factor, MPIP Max Planck Institute of Psychiatry
Twelve months of CSH resulted in significant changes in sex hormones in both cohorts. In contrast to our initial hypothesis, we did however not observe any
statistically significant effect of the treatment on BDNF levels in transmen
P-values in italic indicate a significant difference
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BDNF release. In addition to its presence within the
follicular fluid, it has been shown that BDNF is also in-
creased in menstrual blood and also expressed within cells
of the endometrium [39]. As CSH in transmen results in
amenorrhea and therefore ovarian arrest, as well as atro-
phy of the endometrium, a decrease in BDNF would be
the logical consequence. Further studies could therefore,
e.g., in particular focus on the effects of the treatment on
BDNF levels in ovarian and endometrial tissue which
would be available for study purposes as these sexual or-
gans are usually removed during sex reassignment surgery.
It has also been demonstrated before that peripheral
BDNF levels are lower in depressed subjects in compari-
son to healthy controls and that they can be increased fol-
lowing introduction of antidepressant treatment [40, 41].
In this context, BDNF has also been suggested as potential
predictor for remission [40]. The exact mechanism for this
finding has not been completely elucidated so far, but it
seems that this effect is independent of the administered
drug class [40, 41]. Though platelets express serotonin
and noradrenalin receptors and are thereby directly
targeted by antidepressant drugs such as SSRI and
noradrenalin reuptake inhibitors (NARI) [42], there is
also evidence that peripheral BDNF levels do respond
to non-pharmacological antidepressant treatments as
well [43]. Though mood disorders are common in
transsexual individuals [44], we did not observe any
changes in our results if we excluded those patients
that had been pharmacologically treated due to any
psychiatric comorbidity. We thus doubt that alteration
in BDNF levels as observed earlier in transwomen reflects
a particular mood status, as it has been repeatedly re-
ported that there is an improvement in the general
well-being and depressive symptoms in transmen as
well as in transwomen [45, 46], following initiation of
CSH, in particular during the first year of medical
treatment.
Our study results nonetheless challenge the idea that
at least peripheral BDNF levels mediate the macroscopic
brain changes in transmen, observed during CSH, and
rather support the notion that direct effects of testosterone
are responsible for this finding.
We can only speculate if BDNF in this particular set-
ting plays any role in cognitive functioning. There are
only few studies that have investigated the effects of
CSH on cognition in gender dysphoric individuals. CSH
in transwomen seems to have little effects on memory
function [47] though it may, e.g., affect activation patters
in fMRI paradigms including mental rotation tasks [48].
To date, it is not known, whether this effect is directly
attributable to macroscopic changes in brain structure
or a result of altered neuronal activation patterns [49].
In conclusion, our data do not indicate that testosterone
does play a major role in the regulation of peripheral
BDNF in females. However, we cannot exclude that poten-
tial interfering mechanisms, we could not account for in
the present study setting, may have influenced the results.
Additional file
Additional file 1: Table S1. General characteristics and platelet
measures in transwomen. (DOCX 18.5 kb)
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